Posts by: Jose Marques Lopes, PhD

News

Lynparza (olaparib) tablets have been approved by the European Commission as a standalone treatment for adults with a subset of locally advanced or metastatic breast cancer. The decision follows ... Read more

April 10, 2019

FDA Approves Ibrance Combo Therapy for Some Male Breast Cancers

News

The U.S. Food and Drug Administration (FDA) has expanded the use of Ibrance (palbociclib) capsules in combination with an aromatase inhibitor or Faslodex (fulvestrant) to men with a subset of ... Read more

March 11, 2019

NeuVax/Herceptin Combo Promotes Disease-free Survival in TNBC

News

Long-term treatment with a combination of NeuVax (nelipepimut-S) and Herceptin (trastuzumab) is safe and extends the time without disease resurgence in women with triple-negative breast cancer, according to final results of a Phase ... Read more

January 14, 2019

Phase 1b/2 Trial Testing Rebastinib/Chemo Combo in Advanced Cancer Patients Begins

News

A Phase 1b/2 clinical trial testing rebastinib, in combination with the chemotherapy medication carboplatin, in adults with breast cancer and patients with other advanced or metastatic solid tumors has ... Read more

July 11, 2018

Machine Learning Provides Early Lymphedema Detection in Breast Cancer Survivors, Study Reports

News

Lymphedema, a common complication of breast cancer treatment, can be accurately detected with a machine learning approach that uses real-time symptom reports, according to researchers. Their study, “Machine learning for detection ... Read more

July 9, 2018July 9, 2018

Tecentriq-Abraxane Combo Reduces Risk of Worsening Disease, Death in Metastatic Triple Negative Breast Cancer, Phase 3 Trial Shows

News

Adding Tecentriq (atezolizumab) to the chemotherapy Abraxane (nab-paclitaxel) significantly delays the time to worsening disease or death in patients with metastatic triple negative breast cancer (TNBC), a Phase 3 trial shows. The ... Read more

July 6, 2018July 6, 2018

Imfinzi-Chemo Combo Shows Effectiveness in Treating Triple-negative Breast Cancer, Phase 2 Study Shows

News

The combination of Imfinzi (durvalumab) with standard chemotherapy leads to high treatment effectiveness in patients with triple-negative breast cancer (TNBC), a Phase 2 trial shows. The research, “Randomized phase ... Read more

April 20, 2018

FDA Grants Fast Track Status to Breast Cancer Therapy Candidate Balixafortide Combined with Halaven

News

The U.S. Food and Drug Administration granted fast track status to Polyphor’s immuno-oncology candidate balixafortide (POL6326) in combination with Halaven (eribulin mesylate) to treat a subset of patients with ... Read more

April 16, 2018

New Breast Cancer Research Tool Looks at Tumor Biology, Predicts Treatment Response

News

NanoString launched a new research panel to allow for a more rapid and complete view of breast cancer and its associated immune response. The new Breast Cancer 360 (BC 360) ... Read more

April 4, 2018

EMA to Decide if Lynparza Can Treat BRCA-mutated Metastatic Breast Cancer Patients

News

The European Medicines Agency has agreed to review an application by AstraZeneca and MSD requesting the approval of Lynparza (olaparib) for the treatment of patients with a difficult-to-treat type of metastatic breast cancer ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Lynparza Approved in EU to Treat Subset of Advanced Breast Cancer

FDA Approves Ibrance Combo Therapy for Some Male Breast Cancers

NeuVax/Herceptin Combo Promotes Disease-free Survival in TNBC

Phase 1b/2 Trial Testing Rebastinib/Chemo Combo in Advanced Cancer Patients Begins

Machine Learning Provides Early Lymphedema Detection in Breast Cancer Survivors, Study Reports

Tecentriq-Abraxane Combo Reduces Risk of Worsening Disease, Death in Metastatic Triple Negative Breast Cancer, Phase 3 Trial Shows

Imfinzi-Chemo Combo Shows Effectiveness in Treating Triple-negative Breast Cancer, Phase 2 Study Shows

FDA Grants Fast Track Status to Breast Cancer Therapy Candidate Balixafortide Combined with Halaven

New Breast Cancer Research Tool Looks at Tumor Biology, Predicts Treatment Response

EMA to Decide if Lynparza Can Treat BRCA-mutated Metastatic Breast Cancer Patients

Pin It on Pinterest